Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Xenetic Biosciences, Inc. (XBIO) had Consolidated Net Income/Loss of $-0.90M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.59M |
|
$-0.90M |
|
-- |
|
$0.59M |
|
$1.54M |
|
$-0.94M |
|
$0.04M |
|
$-0.90M |
|
$-0.90M |
|
$-0.90M |
|
$-0.90M |
|
|
Consolidated Net Income/Loss |
$-0.90M |
$-0.90M |
|
$-0.94M |
|
$-0.94M |
|
1.54M |
|
1.54M |
|
$-0.59 |
|
$-0.59 |
|
| Balance Sheet Financials | |
$5.48M |
|
-- |
|
$0.31M |
|
$5.79M |
|
$0.67M |
|
-- |
|
-- |
|
$0.67M |
|
$5.12M |
|
$5.12M |
|
$5.12M |
|
1.54M |
|
| Cash Flow Statement Financials | |
$-1.00M |
|
-- |
|
-- |
|
$6.17M |
|
$5.16M |
|
$-1.00M |
|
$0.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.20 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-158.85% |
|
-158.85% |
|
-- |
|
-152.23% |
|
-152.23% |
|
$-1.00M |
|
-- |
|
-- |
|
-- |
|
0.10 |
|
-- |
|
-- |
|
-- |
|
-17.63% |
|
-17.63% |
|
-15.60% |
|
-17.63% |
|
$3.32 |
|
$-0.65 |
|
$-0.65 |
|